1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Living Cell Technologies Limited

Living Cell Technologies Limited

LVCLY
Living Cell Technologies LimitedUS flagOther OTC
0.03
USD
+0.01
- -
11.39MMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
0.01
0.1
0.2
0.2
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.22
0.16
-0.08
-0.18
-0.17
-0.07
-0.07
-0.01
-0.05
-0.02
-0.02
-0.02
-0.02
Free Cash Flow per Basic Share
-0.19
-0.07
0.03
- -
-0.08
-0.07
-0.06
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.18
0.36
0.28
0.11
0.03
0.04
0.06
0.06
- -
-0.02
-0.04
- -
- -
Tangible Book Value per Share
0.21
0.4
0.35
0.22
0.12
0.12
0.13
0.12
0.07
0.05
0.02
0.05
0.03
Basic Weighted Avg Shares
31
36
38
38
43
47
57
57
61
61
61
89
135
Sales/Revenue/Turnover
- -
4
8
7
1
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-5,050.78
-114.78
-15.2
-21.4
-537.56
-3,360.95
-4,556.28
-3,517.78
-42,607.46
-99,835.86
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-7
6
-3
-7
-7
-3
-4
- -
-3
-1
-1
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-3,849.43
153.07
-39.3
-91.68
-1,150.97
-2,575.68
-3,548.14
-308.47
-32,565.9
-30,570.36
- -
- -
- -
Working Capital
4
2
4
4
5
5
7
7
4
3
1
4
4
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
7
14
13
8
5
6
8
7
4
3
1
4
4
Return on Invested Capital (%)
- -
-40.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
60.22
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-129.91
60.65
-25.24
-92.24
-268.62
-218.73
-156.33
-11.12
-198.32
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.41%
12.32%
-6.76%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
78.92%
154.49%
7.68%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.02
2022
- -
- -
- -
- -
-0.02
2023
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
David Richard Hainsworth
Full Time Employees
48
Sector
Healthcare
Industry
Biotechnology
Address
Tower 2 Sydney NSW Australia 2000
IPO Date
Jan 30, 2008
Website
lctglobal.com
Similar Companies
PHAXIAM Therapeutics S.A. (PHXM.PA)
Jyong Biotech Ltd. Ordinary Shares (MENS)
CASI Pharmaceuticals, Inc. (CASI)
Simcere Pharmaceutical Group Limited (2096.HK)
MediciNova, Inc. (MNOV)
Molecular Partners AG (0QXX.L)
Business
Living Cell Technologies Limited (LVCLY) is an Australian biotechnology company focused on developing and commercializing cell-based therapies for chronic diseases, particularly diabetes and neurological disorders. The company offers proprietary products including DIABECELL, an encapsulated porcine pancreatic islet cell therapy designed to restore insulin production in patients with insulin-dependent diabetes; and NTCELL, a porcine choroid plexus cell therapy aimed at neuroprotection and repair for conditions such as Huntington's disease and stroke. These therapies utilize Living Cell's unique Live Cell Microencapsulation technology to protect foreign cells from immune rejection while enabling their therapeutic function; the company also provides research services and contract manufacturing for cell-based therapeutics. Founded in 1987 and headquartered in Auckland, New Zealand, with additional operations in Australia and clinical development activities across North America and Europe, Living Cell Technologies targets patients with Type 1 diabetes and neurodegenerative diseases through clinical trials and regulatory approvals. In recent developments, the company completed a strategic merger with Neurizon Therapeutics in 2023, expanding its pipeline into neurodegenerative therapies and enhancing its manufacturing capabilities; it also secured AUD 10 million in funding in 2024 to advance Phase II trials for DIABECELL and initiated a new partnership with a U.S.-based contract research organization for accelerated FDA pathway progression.